Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT)

Papers

BMJ 2004; doi: https://doi.org/10.1136/bmj.38043.501690.7C (Published 11 March 2004) Cite this as: BMJ 2004;:bmj;bmj.38043.501690.7Cv1

Cited by...

Side effects of acetazolamide: a systematic review and meta-analysis assessing overall risk and dose dependence
- Abstract
- Fulltext
- PDF
Ginkgo biloba extract for prevention of acute mountain sickness: a systematic review and meta-analysis of randomised controlled trials
- Abstract
- Fulltext
- PDF
Tibetan plateau earthquake: altitude challenges to medical rescue work
- Abstract
- Fulltext
- PDF
Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta-analysis
- Abstract
- Fulltext
- PDF
Travel to high altitude with pre-existing lung disease
- Abstract
- Fulltext
- PDF
Acute mountain sickness: medical problems associated with acute and subacute exposure to hypobaric hypoxia
- Abstract
- Fulltext
- PDF
Ginkgo biloba and acetazolamide for acute mountain sickness: Bias in participants may underestimate effectiveness of agents
- Abstract
- Fulltext
- PDF
Ginkgo biloba and acetazolamide for acute mountain sickness: Exclusion of high risk, low status groups perpetuates discrimination and inequalities
- Abstract
- Fulltext
- PDF